

12 Apr 2021 | News

QUOTED. 12 April 2020. Mike Dale.

by

Abbott has received two CE marks, expanding access to the company's TriClip minimally invasive tricuspid valve repair technology and its market-leading Xience everolimus-eluting coronary stent. Mike Dale, senior vice president of Abbott's structural heart business, explained the significance of the news.

"Tricuspid regurgitation is considered the most undertreated valve issue. Our novel TriClip therapy offers the best possible outcomes for people suffering from a debilitating condition and gives doctors even more options for customizing repair of this complex anatomy." – Mike Dale, senior vice president, structural heart, Abbott

- Find out more: [Abbott Gains CE Marks For New Tricuspid Device And Expanded Xience DES Indication](#)

[Click here](#) for a free trial of *Medtech Insight*